Who Owns AtriCure Company?

AtriCure Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns AtriCure?

Understanding AtriCure's ownership reveals its strategic direction and accountability. Its 2005 NASDAQ IPO was a key moment, shifting it from private to public, expanding its shareholder base and increasing oversight.

Founded in 2000 by Michael Hooven, AtriCure, Inc. is a leader in cardiac arrhythmia treatment, holding about 60% of the surgical Afib ablation market. Its journey from a startup to a publicly traded company has shaped its ownership landscape significantly.

As of August 2025, AtriCure's market capitalization stands at approximately $1.76 billion. This valuation underscores its strong market presence and growth trajectory in the healthcare sector. Exploring its ownership evolution, from founding stakes to institutional and individual investors, provides insight into its control and strategic path, including innovations like those detailed in the AtriCure PESTEL Analysis.

AtriCure, Inc. was established in 2000 by Michael Hooven, an entrepreneur with extensive experience in the medical device sector. Hooven's vision was to address a significant unmet need in the treatment of atrial fibrillation by developing innovative surgical solutions. While Hooven is recognized as the founder, specific details regarding the initial equity distribution among the founding team are not publicly disclosed in recent reports.

Founder's Vision Michael Hooven founded AtriCure in 2000 with a focus on surgical treatments for cardiac arrhythmias. His background in physics and mechanical engineering informed the company's early technological direction. Early Funding The company's initial research and development were primarily supported by venture capital investments. This early financial backing was crucial for bringing its innovative cardiac surgery technologies to fruition. Unmet Medical Need AtriCure was established to address a critical gap in the market for effective surgical interventions for atrial fibrillation. This focus has remained central to the company's strategy. Initial Ownership Details Precise details on initial equity splits or shareholding percentages among founders are not publicly available. Recent reports from 2024-2025 do not highlight any early ownership disputes or buyouts. Strategic Direction The founding team's commitment to innovative surgical solutions for Afib has shaped the company's strategic path. This early vision continues to influence AtriCure's development and market approach. Venture Capital Role Venture capital played a pivotal role in funding AtriCure's early stages, enabling the development and refinement of its specialized medical devices. This investment was key to its initial growth.

The foundational period of AtriCure was characterized by a clear mission to innovate within the cardiac surgery space, driven by the founder's expertise and vision. Early financial support from venture capital firms was instrumental in translating this vision into tangible product development, laying the groundwork for the company's future growth and its position in the market for treating cardiac arrhythmias. For a deeper understanding of the company's origins, one can refer to the Brief History of AtriCure.

Key Aspects of AtriCure's Founding

AtriCure's inception in 2000 was driven by a specific market need and the founder's technical background. The company's early trajectory was significantly shaped by external funding and a focused strategic objective.

• Founded in 2000 by Michael Hooven.
• Focus on surgical solutions for atrial fibrillation.
• Initial funding primarily from venture capital.
• Founder possesses expertise in physics and mechanical engineering.
• No publicly detailed early ownership disputes or buyouts.

AtriCure SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

AtriCure's ownership journey saw a significant shift with its NASDAQ IPO in August 2005, trading under the symbol ATRC. This event marked its transition into a publicly traded entity, setting the stage for its subsequent growth and market presence.

The ownership landscape of AtriCure (ATRC) is largely dominated by institutional investors, reflecting broad confidence in the company's market strategy and performance. As of mid-2025, these entities collectively hold approximately 81.46% of the company's stock, underscoring their significant influence on AtriCure company ownership. Insiders represent a smaller but notable portion at 3.55%, while public companies and individual investors account for the remaining 14.99% of AtriCure stock ownership.

Major AtriCure Shareholders

Institutional investors are the primary holders of AtriCure stock. These large entities play a crucial role in the company's financial direction and strategy.

• The Vanguard Group, Inc. holds 9.87% of shares as of June 30, 2025.
• BlackRock, Inc. is another significant institutional stakeholder.
• Wellington Management Group Llp and AllianceBernstein L.P. also maintain substantial holdings.
• Other key institutional owners include Hood River Capital Management LLC and Macquarie Group Ltd.

Under the leadership of President and CEO Michael H. Carrel, AtriCure has strategically expanded its capabilities through key acquisitions. The integration of Estech, nContact, and SentreHEART has bolstered its offerings in ablation and appendage management technologies. These strategic moves are integral to the Growth Strategy of AtriCure, reinforcing its commitment to advancing cardiac patient care and solidifying its leadership in the cardiac surgery sector.

AtriCure PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The strategic direction and governance of AtriCure, Inc. are guided by its executive leadership and Board of Directors. As of March 28, 2025, the Board comprises eight nominees for election, including William W. Burke, Valerie L. Asbury, Sheri L. Dodd, Raymond O. Huggenberger, Laura G. King, D. Brent Shafer, Carmen B. Volkart, and B. Vindell Washington. Michael H. Carrel has been President, CEO, and a director since November 2012.

AtriCure's Board of Directors operates without a classified structure, meaning each director serves a one-year term, concluding at the subsequent annual stockholder meeting. Removal of a director requires a significant affirmative vote of at least 75% of the total votes eligible for director elections. Publicly available information, including recent proxy statements, does not indicate the existence of dual-class shares or other arrangements that would confer disproportionate control or special voting rights beyond the standard one-share-one-vote principle for common stock, which is a key aspect of understanding AtriCure company ownership.

Governance and Shareholder Engagement

Institutional Shareholder Services (ISS) and Glass Lewis recommended voting against AtriCure's Say-on-Pay Proposal in 2025. The company responded by reiterating its commitment to a pay-for-performance compensation strategy.

• Focus on aligning executive pay with company performance.
• Commitment to creating long-term stockholder value.
• Transparency in compensation practices.
• Addressing shareholder concerns regarding executive compensation.
• Understanding the Revenue Streams & Business Model of AtriCure provides context for compensation decisions.

AtriCure Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent financial performance and strategic product developments have shaped the ownership trends for AtriCure over the past three to five years. The company's growth trajectory influences its shareholder base and the dynamics of its stock ownership.

Insider trading activity in 2025 indicates ongoing adjustments in executive and director holdings. In August 2025, filings showed both proposed sales of shares received as compensation and acquisitions and sales of shares by a director. Collectively, insiders increased their holdings from 4.28% to 4.41% in May 2025. While a public offering in May 2020 raised approximately $175 million, there have been no major secondary offerings or significant share buybacks reported in 2024-2025 that would drastically alter overall AtriCure stock ownership percentages. Institutional investors continue to hold a substantial majority of the company's stock, reflecting broader industry trends of increased institutional ownership.

Product Innovations Driving Growth

AtriCure launched several new products in 2024 and 2025, including the EnCompass clamp and cryoICE cryoXT probe. These innovations are key to the company's strategy.

Clinical Trial Milestones

The company completed enrollment for the LeAAPS trial in July 2025, involving over 6,500 patients. This trial is expected to enhance the company's market position.

Future Revenue Targets

AtriCure has set a long-term goal of achieving $1 billion in revenue by 2030. This ambitious target suggests potential future strategic moves that could impact AtriCure company ownership.

Market Position and Ownership

The company's focus on market penetration and physician adoption, alongside its product pipeline, contributes to its overall value. Understanding the Competitors Landscape of AtriCure can provide further context on its market standing and ownership dynamics.

AtriCure Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔